• Polyrizon signed first U.S. clinical trial agreement with an allergy-focused clinical research site in Texas to start human testing of NASARIX (PL-14) seasonal allergic rhinitis nasal spray.
• Texas site set to serve as first center in planned multi-center study comparing PL-14 efficacy, safety, tolerability versus saline spray.
• Agreement marks initial U.S. site activation step ahead of planned first-in-human clinical program; additional sites expected in coming months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130925PRIMZONEFULLFEED9719374) on May 13, 2026, and is solely responsible for the information contained therein.